We are improving our search experience. To check which content you have full access to, or for advanced search, go back to the old search.

Search

Please fill in this field.

Search Results

Showing 41-60 of 10,000 results
  1. Longitudinal dynamic changes in factor VIII inhibitor titers in patients with hemophilia A and inhibitors receiving emicizumab prophylaxis

    Emicizumab prophylaxis dramatically reduces bleeding events in patients with hemophilia A (PwHA) with or without factor VIII (FVIII) inhibitors....

    Naruto Shimonishi, Kana Sasai, ... Keiji Nogami in International Journal of Hematology
    Article 06 October 2023
  2. Antibiotic prophylaxis in posterior colporrhaphy does not reduce postoperative infection: a nationwide observational cohort study

    Introduction and hypothesis

    The aim of this study was to explore if antibiotic prophylaxis prevents postoperative infection after a posterior...

    Vilhelm Mörlin, Denise Golmann, ... Ida Bergman in International Urogynecology Journal
    Article 08 August 2023
  3. Efficacy of antibiotic prophylaxis for reducing capsular contracture in prosthesis-based breast surgery: a systemic review and meta-analysis

    Antibiotics Prophylaxis to prevent capsular contracture in prosthesis-based breast surgery is common in clinical practice. However, there is...

    Pengcheng Liu, Yuting Song, ... Zhengyong Li in Updates in Surgery
    Article 23 February 2024
  4. Central Nervous System Prophylaxis and Treatment in Acute Leukemias

    Improvements in systemic therapy in the treatment of acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML) have improved patient...

    Susan Y. Wu, Nicholas J. Short, ... Penny Q. Fang in Current Treatment Options in Oncology
    Article Open access 13 December 2022
  5. Adherence to Extended Venous Thromboembolism Prophylaxis and Outcomes After Complex Gastrointestinal Oncologic Surgery

    Background

    Clinical guidelines recommend extended venous thromboembolism (VTE) prophylaxis for cancer patients after major gastrointestinal (GI)...

    Michail N. Mavros, Lauren A. Johnson, ... Bradley C. Martin in Annals of Surgical Oncology
    Article Open access 20 June 2023
  6. Real-world efficacy of antibiotic prophylaxis for upper gastrointestinal bleeding in cirrhotic patients in Japan

    Background and Aims

    Antibiotic prophylaxis is recommended for cirrhotic patients with upper gastrointestinal bleeding (UGIB). However, the frequency...

    Masayuki Ueno, Takashi Fujiwara, ... Motowo Mizuno in Journal of Gastroenterology
    Article 12 May 2023
  7. Norfloxacin versus alternative antibiotics for prophylaxis of spontaneous bacteria peritonitis in cirrhosis: a systematic review and meta-analysis

    Background

    Spontaneous bacterial peritonitis (SBP) is a life-threatening complication in patients with advanced cirrhosis. Prophylactic Norfloxacin...

    Shuailing Song, Yi Yang, ... **ao Li in BMC Infectious Diseases
    Article Open access 28 August 2023
  8. Perioperative antibiotic prophylaxis in the setting of cochlear implantation: a retrospective analysis of 700 cases

    Purpose

    Postoperative wound infections after cochlear implantation are rare but sometimes serious and can lead to explantation. Therefore,...

    Katharina Schaumann, D. Mütz, ... T. Klenzner in European Archives of Oto-Rhino-Laryngology
    Article Open access 14 March 2024
  9. Antifungal Prophylaxis and Treatment of Breakthrough Invasive Fungal Diseases in High-Risk Hematology Patients: A Prospective Observational Multicenter Study

    We aimed to investigate the approaches for antifungal prophylaxis (AFP) and antifungal treatment in breakthrough invasive fungal diseases (IFDs)...

    Gökhan Metan, Ayşe Çiftçioğlu, ... Şeniz Öngören in Indian Journal of Hematology and Blood Transfusion
    Article 20 May 2024
  10. Effect of Pneumocystis jirovecii pneumonia prophylaxis on hematologic toxicity in patients receiving chemoradiation for primary brain tumors

    Purpose

    Diffuse gliomas are managed with radiation and temozolomide; however, this therapy often results in hematologic toxicities. Patients...

    Lisa M. Arnold, Yoji Hoshina, ... Joe Mendez in Journal of Neuro-Oncology
    Article 16 February 2024
  11. Primary vs. pre-emptive anti-seizure medication prophylaxis in anti-CD19 CAR T-cell therapy

    Introduction

    Seizures may occur in up to 30% of non-Hodgkin lymphoma patients who received anti-CD19 CAR T-cell therapy, yet the optimal anti-seizure...

    Umberto Pensato, Federica Pondrelli, ... Stefania Bramanti in Neurological Sciences
    Article Open access 21 March 2024
  12. Cost-Effectiveness of Recombinant Factor IX Fc Prophylaxis and Recombinant Factor IX On-Demand Treatment in Patients with Haemophilia B Without Inhibitors

    Introduction

    Recombinant factor IX (rFIX) and recombinant FIX Fc fusion protein (rFIXFc) are standard half-life and extended half-life FIX replacement...

    Michal Pochopien, Anna Tytuła, ... Daniel Eriksson in Advances in Therapy
    Article Open access 23 April 2024
  13. Real-World Effectiveness of rFIXFc Prophylaxis in Patients with Haemophilia B Switched from Standard Half-Life Therapy in Three European Countries

    Introduction

    The current study describes real-world clinical outcomes and factor usage among patients with haemophilia B switching from standard...

    Eva Funding, Gillian Lowe, ... Carly Rich in Advances in Therapy
    Article Open access 23 June 2023
  14. Nephrotic-range proteinuria: a potential risk factor for failure of tixagevimab-cilgavimab prophylaxis

    Background

    Pre-exposure prophylaxis with tixagevimab-cilgavimab has been shown to reduce the incidence of SARS-CoV-2 infection in immunocompromised...

    Ayman Al Jurdi, Christopher El Mouhayyar, ... Leonardo V. Riella in Journal of Nephrology
    Article 02 September 2023
  15. Antibiotic choice for Group B Streptococcus prophylaxis in mothers with reported penicillin allergy and associated newborn outcomes

    Objective

    To evaluate the choice of antibiotic used for intrapartum Group B Streptococcus (GBS) prophylaxis in pregnant individuals with reported...

    Josephine B. Snider, Leena B. Mithal, ... Moeun Son in BMC Pregnancy and Childbirth
    Article Open access 30 May 2023
  16. Letermovir safety and efficacy for cytomegalovirus prophylaxis in adult Japanese kidney transplant recipients: a multicenter, open-label, noncomparative Phase 3 study

    Background

    Letermovir is approved for cytomegalovirus (CMV) prophylaxis in adult allogeneic hematopoietic cell transplantation recipients worldwide...

    Hideki Ishida, Norihiko Goto, ... Barbara Haber in Clinical and Experimental Nephrology
    Article Open access 13 April 2024
  17. Cost-Effectiveness Analysis of Etranacogene Dezaparvovec Versus Extended Half-Life Prophylaxis for Moderate-to-Severe Haemophilia B in Germany

    Background and Objective

    Haemophilia B is a rare genetic disease that is caused by a deficiency of coagulation factor IX (FIX) in the blood and leads...

    Niklaus Meier, Hendrik Fuchs, ... Matthias Schwenkglenks in PharmacoEconomics - Open
    Article Open access 23 March 2024
  18. Prolonged efficacy of cefazolin in intraosseous regional prophylaxis for total knee arthroplasty: a rabbit model study

    Background

    A novel approach known as intraosseous regional administration (IORA) has emerged as a technique for delivering prophylactic antibiotics,...

    **g-Yu Zhang, Ling-Chen Ye, ... Ren-Jie Xu in BMC Musculoskeletal Disorders
    Article Open access 01 February 2024
  19. Moderate- to vigorous-intensity physical activities for hemophilia A patients during low-dose pharmacokinetic-guided extended half-life factor VIII prophylaxis

    Background

    Low-dose pharmacokinetic (PK)-guided extended half-life (EHL) factor VIII (FVIII) prophylaxis can reduce the bleeding risk in hemophilia A...

    Chonlatis Srichumpuang, Arunothai Rakmanotham, ... Darintr Sosothikul in Orphanet Journal of Rare Diseases
    Article Open access 26 March 2024
  20. Ambulatory cancer patients: who should definitely receive antithrombotic prophylaxis and who should never receive

    Up to 15–20% of cancer patients experience one or more episodes of venous thromboembolism during cancer disease. Approximately 80% of all...

    Melina Verso, Andres Muñoz, Jean M. Connors in Internal and Emergency Medicine
    Article 25 May 2023
Did you find what you were looking for? Share feedback.